Drug intelligence / Profile preview

Natural human interferon alfa

Development stage: Unknown
Lead developer: Hayashibara International
Modality: Recombinant Proteins and Enzymes
Administration: Intramuscular, Subcutaneous, Intravenous, Intralesional

Overview

A proprietary preparation of natural human interferon alfa (IFN alfa) with potential immunomodulatory and antineoplastic activities. Interferon alfas are cytokines that modulate the immune response and have been investigated for their ability to inhibit tumor cell proliferation and enhance the activity of immune cells against cancer cells. The specific formulation "OPC-18" refers to a naturally derived version of IFN-alfa, though further details on its clinical development or approval status are limited[1].

Other names: natural human interferon alpha OPC-18IFN alpha OPC-18

Targets

IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on Natural human interferon alfa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Natural human interferon alfa.

Explore the full profile